Efficacy and Safety of Immunosuppressive Therapy for PBC-AIH Overlap Syndrome Accompanied by Decompensated Cirrhosis: A Real-World Study

摘要

Autoimmune liver disease (AILD) comprises a group of immune-mediated liver diseases that include autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC) [1]. The occurrence of overlapping syndromes at different disease stages (so-called overlap syndromes) is not rare, with PBC-AIH overlap syndrome being the most common [2]. The prevalence of PBC-AIH overlap syndrome is approximately 8-10% in adult patients with either PBC or AIH [3, 4], and this low incidence contributes to imprecise diagnostic criteria; furthermore, no standard therapy is currently available. According to the most recent guidelines based on the results of small studies, a combination of ursodeoxycholic acid (UDCA) and immunosuppressants is often recommended for PBC-AIH in clinical practice [5-7].